Vanderbilt Ingram Cancer Center Archives
Funding renewed for Meharry, TSU, Vanderbilt-Ingram partnership on cancer disparities
Sep. 24, 2021—The Meharry Medical College/Vanderbilt-Ingram Cancer Center/Tennessee State University Partnership has received renewed funding from the NCI to continue long-standing collaborations to eliminate cancer health disparities.
Clinical trial tests ATR inhibitor in difficult-to-treat cancers
Sep. 23, 2021— by Tom Wilemon A clinical trial has been launched to test a new targeted therapy in patients with advanced and difficult-to-treat cancers. Satya Das, MD, MSCI, assistant professor of Medicine at Vanderbilt-Ingram Cancer Center (VICC), is the national principal investigator for the trial (NCT04514497) that is now enrolling people with metastatic small cell lung...
Eng named co-chair of NCI clinical trials steering committee
Sep. 23, 2021—Vanderbilt's Cathy Eng, MD, has been elected co-chair of the National Cancer Institute (NCI) Gastrointestinal Cancer Steering Committee.
Structural variants in breast cancer risk genes
Sep. 16, 2021—Vanderbilt epidemiologists conducted in-depth whole genome sequencing of breast cancer risk genes in Black women, who die at higher rates and have more aggressive disease, to discover mutations that may improve testing and treatment selection.
Novel immunotherapy shows robust response for multiple myeloma
Sep. 10, 2021—Vanderbilt research found that a novel immunotherapy demonstrated robust effectiveness in treating relapsed or refractory multiple myeloma.
Discovery offers insight for development of cancer therapies targeting mutant p53
Sep. 2, 2021—Vanderbilt researchers have discovered that aneuploidy (an abnormal number of chromosomes) drives malignant phenotypes in cells expressing mutant p53, a tumor suppressor protein that is mutated in more than half of all human cancers.
Expression atlas for cell regulators
Aug. 19, 2021—Vanderbilt researchers report a comprehensive tissue-specific atlas of protein and mRNA expression for p63 and p73, members of the p53 family signaling network that is the most frequent target of mutations in human cancers.
Park named to new role as deputy director of Vanderbilt-Ingram Cancer Center
Aug. 19, 2021—Ben Ho Park, MD, PhD, Cornelius Abernathy Professor of Medicine, has been named deputy director of Vanderbilt-Ingram Cancer Center (VICC).
Supporting ovarian cancer research
Aug. 19, 2021—Rocker George Thorogood recently made a donation to Vanderbilt-Ingram Cancer Center (VICC) from the Marla Thorogood Memorial Fund for Ovarian Cancer Research.
Jackson elected fellow of American Association of Nurse Practitioners
Aug. 19, 2021—Heather Jackson, PhD, APRN, FNP-BC, NEA-BC, administrative director of Advanced Practice for Vanderbilt-Ingram Cancer Center (VICC), has been elected a fellow of the American Association of Nurse Practitioners (FAANP).
New Clinician Spotlight: Sonya Reid
Aug. 5, 2021—Sonya Reid, MD, MPH, assistant professor of Medicine in the Division of Hematology Oncology, is a member of the Vanderbilt-Ingram Cancer Center Breast Cancer Research Program and sees patients at Vanderbilt Health One Hundred Oaks.
Clinical trial to test immunotherapy for rectal cancer
Aug. 5, 2021—A new clinical trial seeks to determine whether immunotherapy in combination with short-course radiation followed by surgical resection could be a curative treatment for locally advanced rectal cancer.
